hai Application No PCT/JP2004/013722

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C1201/68 G01N33/50 GO1N33/574

According to International Patent Classification (IPC) or to both national classification and IPC

### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, Sequence Search, CHEM ABS Data, WPI Data, PAJ

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of	the relevant passages	Relevant to claim No.
X	OKABE H ET AL: "Genome-wide gene expression in human hepa carcinomas using cDNA microar Identification of genes invol carcinogenesis and tumor prog CANCER RESEARCH, AMERICAN ASS CANCER RESEARCH, BALTIMORE, M vol. 61, no. 5, 1 March 2001 pages 2129-2137, XP002235524 ISSN: 0008-5472	tocellular ray: ved in viral ression" OCIATION FOR ID, US,	1–7
Y	cited in the application Hs.42949 corresponds to HES6 abstract page 2129, column 2, paragrap 2131, column 1, paragraph 2 page 2133, column 2, paragrap page 2137, column 2, paragrap	h 2	8-13, 15-19,23
X Furti	ner documents are listed in the continuation of box C.	Patent family members are listed	n annex.
"A" docume consider of filing docume which citation other r	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	general state of the art which is not agricular relevance ublished on or after the international state of the art which is not articular relevance ublished on or after the international ublished after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.	
	actual completion of the international search	Date of mailing of the International sea	rch report
1	7 March 2005	07/04/2005	
Name and n	nailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo ni.	Authorized officer Tilkorn, A-C	

Interior nal Application No
PCT/JP2004/013722

		PCT/JP2004/013722					
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT							
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.					
X Y	WO 03/008578 A (BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS; PRIMIANO, THOMAS; CHA) 30 January 2003 (2003-01-30) SEQ ID NO: 99 abstract	14,21, 22,25 8-13,					
	page 8, line 15 - page 9, line 8 page 10, line 22 - line 31 page 13, line 32 - page 15, line 28 page 24, line 1 - line 23 page 38, line 23 - line 28 tables 1,3,4	15-19,23					
A	THOMPSON J D: "Applications of antisense and siRNAs during preclinical drug development" DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 7, no. 17, 1 September 2002 (2002-09-01), pages 912-917, XP002236964 ISSN: 1359-6446 the whole document	16,17, 21,22,25					
A	WO 03/027143 A (JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO; ONCO) 3 April 2003 (2003-04-03) the whole document	1-19, 21-23,25					
A	WO 03/025228 A (PROTEOLOGICS, INC; REISS, YUVAL; ALROY, IRIS) 27 March 2003 (2003-03-27) the whole document	1-19, 21-23, 25					

International application No. PCT/JP2004/013722

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 15-19 (with respect to IA) because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 15-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X Claims Nos.: 20, 24 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
No required additional search fees were timely hald by the applicant. Consequently, this International Search Report is
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 15-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 20.24

Claims 20 and 24 lack clarity (Art 6 PCT) because they do not allow the definition of any structural feature of the compounds to be used in the method or incorporated in the composition respectively. However, such a feature is essential to understand the scope of the claims. Since the description provides no examples of any such componds. no search at all was possible with respect to claims 20 and 24.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

information on patent family members

Interior nal Application No
PCT/JP2004/013722

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 03008578	A	30-01-2003	CA	2454423	A1	30-01-2003
			EP	1427855	A2	16-06-2004
			WO	03008578	A2	30-01-2003
			WO	03007884	A2	30-01-2003
			US	2003180739	A1	25-09-2003
WO 03027143	 А	03-04-2003	EP	1434879	A2	07-07-2004
			EP	1430152	A2	23-06-2004
			WO	03027322	A2	03-04-2003
			WO	03027143	A2	03-04-2003
			JP	2005503176	T	03-02-2005
			US	2005019768	A1	27-01-2005
			US	2004235018	A1	25-11-2004
		_	CA	2399569	A1	25-03-2003
WO 03025228	A	27-03-2003	WO	03025228	A1	27-03-2003
			US	2005004017	A1	06-01-2005